Cargando…
High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer
BACKGROUND: Prostate cancer (PC) can be stratified into distinct molecular subtypes based on TMPRSS2-ERG gene fusion status, but its potential prognostic value remains controversial. Likewise, routine clinicopathological features cannot clearly distinguish aggressive from indolent tumors at the time...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608326/ https://www.ncbi.nlm.nih.gov/pubmed/26478752 http://dx.doi.org/10.1186/s13148-015-0146-5 |
_version_ | 1782395653835456512 |
---|---|
author | Strand, Siri H. Hoyer, Soren Lynnerup, Anne-Sofie Haldrup, Christa Storebjerg, Tine Maj Borre, Michael Orntoft, Torben F. Sorensen, Karina D. |
author_facet | Strand, Siri H. Hoyer, Soren Lynnerup, Anne-Sofie Haldrup, Christa Storebjerg, Tine Maj Borre, Michael Orntoft, Torben F. Sorensen, Karina D. |
author_sort | Strand, Siri H. |
collection | PubMed |
description | BACKGROUND: Prostate cancer (PC) can be stratified into distinct molecular subtypes based on TMPRSS2-ERG gene fusion status, but its potential prognostic value remains controversial. Likewise, routine clinicopathological features cannot clearly distinguish aggressive from indolent tumors at the time of diagnosis; thus, new prognostic biomarkers are urgently needed. The DNA methylation variant 5-hydroxymethylcytosine (5hmC, an oxidized derivative of 5-methylcytosine) has recently emerged as a new diagnostic and/or prognostic biomarker candidate for several human malignancies. However, this remains to be systematically investigated for PC. In this study, we determined 5hmC levels in 311 PC (stratified by ERG status) and 228 adjacent non-malignant (NM) prostate tissue specimens by immunohistochemical analysis of a tissue microarray, representing a large radical prostatectomy (RP) cohort with long clinical follow-up. We investigated possible correlations between 5hmC and routine clinicopathological variables and assessed the prognostic potential of 5hmC by Kaplan-Meier and uni- and multivariate Cox regression analyses in ERG+ (n = 178) vs. ERG− (n = 133) PCs using biochemical recurrence (BCR) as endpoint. RESULTS: We observed a borderline significant (p = 0.06) reduction in 5hmC levels in PC compared to NM tissue samples, which was explained by a highly significant (p < 0.001) loss of 5hmC in ERG− PCs. ERG status was not predictive of BCR in this cohort (p = 0.73), and no significant association was found between BCR and 5hmC levels in ERG+ PCs (p = 0.98). In contrast, high 5hmC immunoreactivity was a significant adverse predictor of BCR after RP in ERG− PCs, independent of Gleason score, pathological tumor stage, surgical margin status, and pre-operative prostate-specific antigen (PSA) level (hazard ratio (HR) (95 % confidence interval (CI)): 1.62 (1.15–2.28), p = 0.006). CONCLUSIONS: This is the first study to demonstrate a prognostic potential for 5hmC in PC. Our findings highlight the importance of ERG stratification in PC biomarker studies and suggest that epigenetic mechanisms involving 5hmC are important for the development and/or progression of ERG− PC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-015-0146-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4608326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46083262015-10-17 High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer Strand, Siri H. Hoyer, Soren Lynnerup, Anne-Sofie Haldrup, Christa Storebjerg, Tine Maj Borre, Michael Orntoft, Torben F. Sorensen, Karina D. Clin Epigenetics Research BACKGROUND: Prostate cancer (PC) can be stratified into distinct molecular subtypes based on TMPRSS2-ERG gene fusion status, but its potential prognostic value remains controversial. Likewise, routine clinicopathological features cannot clearly distinguish aggressive from indolent tumors at the time of diagnosis; thus, new prognostic biomarkers are urgently needed. The DNA methylation variant 5-hydroxymethylcytosine (5hmC, an oxidized derivative of 5-methylcytosine) has recently emerged as a new diagnostic and/or prognostic biomarker candidate for several human malignancies. However, this remains to be systematically investigated for PC. In this study, we determined 5hmC levels in 311 PC (stratified by ERG status) and 228 adjacent non-malignant (NM) prostate tissue specimens by immunohistochemical analysis of a tissue microarray, representing a large radical prostatectomy (RP) cohort with long clinical follow-up. We investigated possible correlations between 5hmC and routine clinicopathological variables and assessed the prognostic potential of 5hmC by Kaplan-Meier and uni- and multivariate Cox regression analyses in ERG+ (n = 178) vs. ERG− (n = 133) PCs using biochemical recurrence (BCR) as endpoint. RESULTS: We observed a borderline significant (p = 0.06) reduction in 5hmC levels in PC compared to NM tissue samples, which was explained by a highly significant (p < 0.001) loss of 5hmC in ERG− PCs. ERG status was not predictive of BCR in this cohort (p = 0.73), and no significant association was found between BCR and 5hmC levels in ERG+ PCs (p = 0.98). In contrast, high 5hmC immunoreactivity was a significant adverse predictor of BCR after RP in ERG− PCs, independent of Gleason score, pathological tumor stage, surgical margin status, and pre-operative prostate-specific antigen (PSA) level (hazard ratio (HR) (95 % confidence interval (CI)): 1.62 (1.15–2.28), p = 0.006). CONCLUSIONS: This is the first study to demonstrate a prognostic potential for 5hmC in PC. Our findings highlight the importance of ERG stratification in PC biomarker studies and suggest that epigenetic mechanisms involving 5hmC are important for the development and/or progression of ERG− PC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-015-0146-5) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-15 /pmc/articles/PMC4608326/ /pubmed/26478752 http://dx.doi.org/10.1186/s13148-015-0146-5 Text en © Strand et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Strand, Siri H. Hoyer, Soren Lynnerup, Anne-Sofie Haldrup, Christa Storebjerg, Tine Maj Borre, Michael Orntoft, Torben F. Sorensen, Karina D. High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer |
title | High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer |
title_full | High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer |
title_fullStr | High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer |
title_full_unstemmed | High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer |
title_short | High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer |
title_sort | high levels of 5-hydroxymethylcytosine (5hmc) is an adverse predictor of biochemical recurrence after prostatectomy in erg-negative prostate cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608326/ https://www.ncbi.nlm.nih.gov/pubmed/26478752 http://dx.doi.org/10.1186/s13148-015-0146-5 |
work_keys_str_mv | AT strandsirih highlevelsof5hydroxymethylcytosine5hmcisanadversepredictorofbiochemicalrecurrenceafterprostatectomyinergnegativeprostatecancer AT hoyersoren highlevelsof5hydroxymethylcytosine5hmcisanadversepredictorofbiochemicalrecurrenceafterprostatectomyinergnegativeprostatecancer AT lynnerupannesofie highlevelsof5hydroxymethylcytosine5hmcisanadversepredictorofbiochemicalrecurrenceafterprostatectomyinergnegativeprostatecancer AT haldrupchrista highlevelsof5hydroxymethylcytosine5hmcisanadversepredictorofbiochemicalrecurrenceafterprostatectomyinergnegativeprostatecancer AT storebjergtinemaj highlevelsof5hydroxymethylcytosine5hmcisanadversepredictorofbiochemicalrecurrenceafterprostatectomyinergnegativeprostatecancer AT borremichael highlevelsof5hydroxymethylcytosine5hmcisanadversepredictorofbiochemicalrecurrenceafterprostatectomyinergnegativeprostatecancer AT orntofttorbenf highlevelsof5hydroxymethylcytosine5hmcisanadversepredictorofbiochemicalrecurrenceafterprostatectomyinergnegativeprostatecancer AT sorensenkarinad highlevelsof5hydroxymethylcytosine5hmcisanadversepredictorofbiochemicalrecurrenceafterprostatectomyinergnegativeprostatecancer |